Bentsur Ron's Form 4 filing
Nuvectis Pharma, Inc. (NVCT) · filed Aug 11, 2023
- Accession no.
- 0001104659-23-090650
- Filed
- Aug 11, 2023
- Trade date
- Aug 8-11, 2023
- Filing delay
- 3 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $4.42K. It was filed 3 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bentsur RonCIK 0001251213 | Director, Officer (Chairman & CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 8, 2023 | Common Stock | PPurchaseAcquired | +120 | $14.83 | +$1,779.6 | 3,232,014 | Direct | |
| Aug 11, 2023 | Common Stock | PPurchaseAcquired | +180 | $14.66 | +$2,638.8 | 3,232,194 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.